Overview of KLOR-CON
KLOR-CON, with the NDC 0245-0360, is a human prescription drug manufactured by Upsher-Smith Laboratories, LLC. It is an oral powder for solution, containing potassium chloride as its active ingredient, with a strength of 1.5 g/1 or 2 g/1[1].
Market Context
Pharmaceutical Market Growth
The overall prescription drug market is expected to grow at a Compound Annual Growth Rate (CAGR) of 9% through 2030. This growth is driven by various factors including increasing demand for healthcare services, advancements in technology, and the need for effective treatments for a wide range of conditions[3].
Competitive Landscape
The pharmaceutical industry is facing significant challenges, including competition from generic drugs and biosimilars. Nearly 37% of life sciences executives view competition from generics and biosimilars as a top trend, which could impact the pricing and market share of branded drugs like KLOR-CON[5].
Pricing Trends
Current Pricing
As of the latest available data, specific pricing details for KLOR-CON (NDC 0245-0360) are not provided in the sources. However, pricing for pharmaceuticals can be influenced by several factors including production costs, market demand, regulatory environments, and competition.
Pricing and Access
Pricing and access to drugs are significant issues facing the life sciences industry. Nearly half of the C-suite executives surveyed expect pricing and access to significantly affect their strategies in 2025. This trend could lead to fluctuations in the pricing of drugs like KLOR-CON as companies navigate these challenges[5].
Regulatory and Market Environment
Marketing Category and Approval
KLOR-CON (NDC 0245-0360) is classified under the Abbreviated New Drug Application (ANDA) category, which indicates it is a generic version of a previously approved drug. It was approved and started marketing on October 23, 2017[1].
Patent and Exclusivity
The original patent for KLOR-CON, if any, would have been filed under the New Drug Application (NDA) category for the extended-release tablet form (NDC 0245-5316), which was approved in 1986. However, the generic version (NDC 0245-0360) does not face the same patent exclusivity issues as branded drugs[4].
Technological and Innovation Trends
Role of AI and Data
The pharmaceutical industry is increasingly adopting artificial intelligence (AI) and leveraging external data to enhance operations. AI is expected to play a significant role in drug development, clinical trial design, and real-time patient monitoring. While these trends may not directly impact the pricing of KLOR-CON, they can influence the overall efficiency and innovation within the industry[2].
Price Projections
General Market Trends
Given the overall growth of the prescription drug market and the competitive landscape, prices for generic drugs like KLOR-CON may remain relatively stable or see moderate increases. The CAGR of 9% for the prescription drug market suggests a growing demand, but this growth must be balanced against the competitive pressures from generics and biosimilars[3].
Specific Projections
Without specific historical pricing data for KLOR-CON (NDC 0245-0360), precise price projections are challenging. However, considering the industry trends:
- Short-term (2025-2027): Prices are likely to remain stable or see a slight increase due to the general market growth and the need for potassium chloride supplements.
- Long-term (2028-2030): The impact of increasing competition from generics and biosimilars, along with potential advancements in technology and changes in regulatory environments, could lead to more dynamic pricing adjustments.
Key Takeaways
- KLOR-CON (NDC 0245-0360) is a generic potassium chloride supplement in oral powder form.
- The pharmaceutical market is expected to grow at a CAGR of 9% through 2030.
- Pricing and access issues, along with competition from generics and biosimilars, are significant concerns.
- AI and data trends are expected to enhance operational efficiencies and drive innovation in the industry.
- Price projections for KLOR-CON are likely to be stable in the short term with potential adjustments in the long term based on market and regulatory changes.
FAQs
Q: What is KLOR-CON (NDC 0245-0360)?
A: KLOR-CON (NDC 0245-0360) is an oral powder for solution containing potassium chloride, used as a supplement.
Q: Who manufactures KLOR-CON?
A: KLOR-CON is manufactured by Upsher-Smith Laboratories, LLC.
Q: What is the expected growth rate of the prescription drug market?
A: The prescription drug market is expected to grow at a CAGR of 9% through 2030.
Q: How does competition from generics and biosimilars affect drug pricing?
A: Competition from generics and biosimilars can lead to lower prices and reduced market share for branded drugs, although KLOR-CON itself is a generic product.
Q: What role does AI play in the pharmaceutical industry?
A: AI is increasingly used in the pharmaceutical industry for drug discovery, clinical trial design, real-time patient monitoring, and enhancing operational efficiencies.
Sources
- FDA.report: NDC 0245-0360 Oral Powder, For Solution KLOR-CON.
- Intelligencia.ai: 2025 Pharma Predictions: AI, Health Tech, and Data Trends to Watch.
- DrugPatentWatch: Latest drug prices and trends for NDC 00054-0319.
- FDA.report: NDC 0245-5316 - KLOR-CON.
- Deloitte Insights: 2025 life sciences outlook.
